Venus Medtech Stock Net Income
| VMTHF Stock | USD 0.27 0.00 0.00% |
As of the 5th of February, Venus Medtech has the Variance of 1.66, risk adjusted performance of (0.11), and Coefficient Of Variation of (642.52). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Venus Medtech, as well as the relationship between them. Please validate Venus Medtech market risk adjusted performance, variance, as well as the relationship between the Variance and skewness to decide if Venus Medtech is priced more or less accurately, providing market reflects its prevalent price of 0.27 per share. As Venus Medtech appears to be a penny stock we also recommend to double-check its information ratio numbers.
Venus Medtech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Venus Medtech's valuation are provided below:Venus Medtech does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Venus |
Venus Medtech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Venus Medtech's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Venus Medtech.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Venus Medtech on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Venus Medtech or generate 0.0% return on investment in Venus Medtech over 90 days. Venus Medtech is related to or competes with Abbott Laboratories, Stryker, Boston Scientific, Medtronic PLC, Siemens Healthineers, Siemens Healthineers, and Edwards Lifesciences. Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internati... More
Venus Medtech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Venus Medtech's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Venus Medtech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 10.0 |
Venus Medtech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Venus Medtech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Venus Medtech's standard deviation. In reality, there are many statistical measures that can use Venus Medtech historical prices to predict the future Venus Medtech's volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.92) |
Venus Medtech February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.91) | |||
| Mean Deviation | 0.3886 | |||
| Coefficient Of Variation | (642.52) | |||
| Standard Deviation | 1.29 | |||
| Variance | 1.66 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.92) | |||
| Maximum Drawdown | 10.0 | |||
| Skewness | (7.20) | |||
| Kurtosis | 53.99 |
Venus Medtech Backtested Returns
Venus Medtech owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.16, which indicates the firm had a -0.16 % return per unit of risk over the last 3 months. Venus Medtech exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Venus Medtech's Risk Adjusted Performance of (0.11), variance of 1.66, and Coefficient Of Variation of (642.52) to confirm the risk estimate we provide. The entity has a beta of 0.23, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Venus Medtech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Venus Medtech is expected to be smaller as well. At this point, Venus Medtech has a negative expected return of -0.21%. Please make sure to validate Venus Medtech's treynor ratio and rate of daily change , to decide if Venus Medtech performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Venus Medtech has no correlation between past and present. Overlapping area represents the amount of predictability between Venus Medtech time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Venus Medtech price movement. The serial correlation of 0.0 indicates that just 0.0% of current Venus Medtech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Venus Medtech reported net income of (373.64 Million). This is 209.48% lower than that of the Healthcare sector and 256.92% lower than that of the Medical Devices industry. The net income for all United States stocks is 165.44% higher than that of the company.
Venus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Venus Medtech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Venus Medtech could also be used in its relative valuation, which is a method of valuing Venus Medtech by comparing valuation metrics of similar companies.Venus Medtech is currently under evaluation in net income category among its peers.
Venus Fundamentals
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0486 | |||
| Profit Margin | (1.19) % | |||
| Operating Margin | (1.18) % | |||
| Current Valuation | 550.27 M | |||
| Shares Outstanding | 441.01 M | |||
| Shares Owned By Insiders | 21.67 % | |||
| Shares Owned By Institutions | 41.22 % | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 2.28 X | |||
| Revenue | 415.86 M | |||
| Gross Profit | 324.34 M | |||
| EBITDA | (324.03 M) | |||
| Net Income | (373.64 M) | |||
| Cash And Equivalents | 2.96 B | |||
| Cash Per Share | 6.75 X | |||
| Total Debt | 70.78 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 16.49 X | |||
| Book Value Per Share | 10.09 X | |||
| Cash Flow From Operations | (456.92 M) | |||
| Earnings Per Share | (0.13) X | |||
| Number Of Employees | 1.04 K | |||
| Beta | 0.19 | |||
| Market Capitalization | 855.6 M | |||
| Total Asset | 5.11 B | |||
| Z Score | 7.2 | |||
| Net Asset | 5.11 B |
About Venus Medtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Venus Medtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Venus Medtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Venus Medtech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Venus Pink Sheet
Venus Medtech financial ratios help investors to determine whether Venus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Venus with respect to the benefits of owning Venus Medtech security.